Winning ARWR Stock Forecast: Arrowhead Pharmaceuticals, Inc Jumped Up 87.41% In 3 Months After Strong Buy Prediction

“The ARO-AAT Phase 1 study provides the first readout on pharmacologic activity for a therapeutic leveraging our proprietary Targeted RNAi Molecule, or TRiM™, platform. We have escalated above a dose that we believe achieves maximal activity, and all doses to date appear to be generally well-tolerated.”

– Chris Anzalone, Ph.D., President and CEO of Arrowhead

(Source: Wikimedia Commons)

For three months since March 28th, 2018, Arrowhead Pharmaceuticals Inc (NYSE: ARWR) has gained 87.41%, becoming one of the most profitable stocks in pharmaceuticals industry. The success

Read More

Quick Win by the Algorithm: Amgen partnership looks to provide significant upside for ARWR in 2018

Stock Prediction Quick Win

Read The Full Forecast